Skip to main content
Log in

Acute on Chronic Ivabradine Overdose: a Case Report

  • Toxicology Observation
  • Published:
Journal of Medical Toxicology Aims and scope Submit manuscript

Abstract

Ivabradine is a newly approved medication which reduces the heart rate by antagonizing the If channel. We report a case of intentional overdose on ivabradine. A 26-year-old female presented after taking 250 mg ivabradine. On arrival, her vital signs and neurologic exam were unremarkable. Within 30 min, her heart rate decreased to 31 bpm, but she remained normotensive with no change in mentation. Her bradycardia resolved after treatment with atropine. She experienced two further bradycardic episodes responsive to atropine; the second episode was associated with hypotension, responsive to a fluid bolus. For the remainder of her hospitalization, she remained hemodynamically stable without further interventions. She was dispositioned to the psychiatry service approximately 36 h post-ingestion with a heart rate of 67 bpm. Laboratory analysis confirmed a serum ivabradine concentration of 525 ng/mL, greater than 50 times the mean level in therapeutic trials. Proposed treatments for ivabradine include activated charcoal, atropine, isoproterenol, and intravenous pacing. Further study is needed to identify ideal treatment modalities.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Traynor K. Ivabradine approved for stable chronic heart failure. Am J Health Syst Pharm. 2015;72(11):896. doi:10.2146/news150037.

    Google Scholar 

  2. Mathiaux F, Dulaurent S, Julia F, Gaulier JM. Case report of ivabradine intoxication. J Anal Toxicol. 2014;38(4):231–2. doi:10.1093/jat/bku015.

    Article  CAS  PubMed  Google Scholar 

  3. Gomez Casal V, Lage Cendon L, Lago Preciado G, Vara Adrio S. Ivabradine poisoning with suicide intention. Med Intensiva. 2015;39:577–9. http://www.medintensiva.org/es/pdf/S0210569115001072/S200/. doi: S0210-5691(15)00107-2.

  4. Hancox J, Melgari D, Dempsey C, Brack K, Mitcheson J, Ng GA. hERG potassium channel inhibition by ivabradine may contribute to QT prolongation and risk of torsades de pointes. Ther Adv Drug Saf. 2015;6(4):177.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Nawarskas JJ, Bowman BN, Anderson JR. Ivabradine: a unique and intriguing medication for treating cardiovascular disease. Cardiol Rev. 2015;23(4):201–11. doi:10.1097/CRD.0000000000000070.

    Article  PubMed  Google Scholar 

  6. Rushworth GF, Lambrakis P, Leslie SJ. Ivabradine: a new rate-limiting therapy for coronary artery disease and heart failure. Ther Adv Drug Saf. 2011;2(1):19–28. doi:10.1177/2042098610393209.

    Article  PubMed  PubMed Central  Google Scholar 

  7. European Medicines Agency. European public assessment report: ivabradine scientific discussion. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000597/WC500043587.pdf. Updated 2005. Accessed 01/04/2016.

  8. Mittal SR. Slow junctional rhythm, QTc prolongation and transient torsades de-pointes following combined use of ivabradine, diltiazem and ranolazine. J Assoc Physicians India. 2014;62(5):426–7.

    CAS  PubMed  Google Scholar 

  9. Cocco G, Jerie P. Torsades de pointes induced by the concomitant use of ivabradine and azithromycin: an unexpected dangerous interaction. Cardiovasc Toxicol. 2015;15(1):104–6. doi:10.1007/s12012-014-9274-y.

    Article  PubMed  Google Scholar 

  10. Martin RI, Pogoryelova O, Koref MS, Bourke JP, Teare MD, Keavney BD. Atrial fibrillation associated with ivabradine treatment: Meta-analysis of randomised controlled trials. Heart. 2014;100(19):1506–10. doi:10.1136/heartjnl-2014-305482.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Zoerner AA, Schroeder C, Kayacelebi AA. A validated, rapid UPLC-MS/MS method for simultaneous ivabradine, reboxetine, and metoprolol analysis in human plasma and its application to clinical trial samples. J Chromatogr B Analyt Technol Biomed Life Sci. 2013;927:105–11. doi:10.1016/j.jchromb.2013.01.016.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

Thanks to Catherine Maskell for translation of reference number 3.

Previous Presentation/Meetings

None

Grant/Other Support

None

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Kevin Maskell.

Ethics declarations

Conflicts of Interest

The authors report no pertinent conflicts of interest.

Sources of Funding

None

Additional information

Disclaimer

The views expressed in this article are those of the authors and do not reflect the official policy or position of the Department of the Army, Department of Defense, or the US Government.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Maskell, K., Tse, A., Wolf, C.E. et al. Acute on Chronic Ivabradine Overdose: a Case Report. J. Med. Toxicol. 12, 189–191 (2016). https://doi.org/10.1007/s13181-016-0537-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13181-016-0537-9

Keywords

Navigation